Objective: To explore the effects of budesonide combined with cetirizine on serum a disintegrin and metalloprotease 33 (ADAM33) and sphingosine-1-phosphate (S1P) levels in children with asthma. Methods: Totally 100 children with bronchial asthma admitted into our hospital from Jun. 2014 to Sept. 2017 were extracted to be divided into the study group and the control group via the random number table

with 50 cases in each group. The control group was given budesonide aerosol inhalation

while the study group additionally received cetirizine on the basis of the control group. The clinical efficacy

disappearance time of clinical symptoms and adverse drug reactions of two groups were compared. Changes of pulmonary function

serum inflammatory factors

ADAM33 and S1P levels of two groups were recorded. Results: The total effective rate of the study group was 92.0%

higher than 72.0% of the control group (P<0.05). The disappearance time of wheezing

cough and dyspnea

length of stay in the study group were significantly shorter than those in the control group (P<0.05). After treatment

the levels of FEV1 and PEF in two groups increased significantly

and the levels of FEV1 and PEF in the study group were higher than those in the control group (P<0.05). After treatment

the levels of IL-6 and TNF-α in the study group were lower than those in the control group (P<0.05)

and serum ADAM33 and S1P in the study group were lower than those in the control group (P<0.05). The incidence of adverse drug reactions was 14.0% in the control group and 18.0% in the observation group

with no statistically significant difference between two groups (P>0.05). Conclusion: Budesonide aerosol inhalation combined with cetirizine can effectively improve the clinical symptoms and the pulmonary function of children with bronchial asthma

reduce the levels of ADAM33 and S1P

release the inflammation injury and improve airway remodeling with higher safety.